San Diego, CA, United States of America

Dana Duey

USPTO Granted Patents = 3 

Average Co-Inventor Count = 2.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Burlingame, CA (US) (2020)
  • San Diego, CA (US) (2022 - 2023)

Company Filing History:


Years Active: 2020-2023

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Dana Duey: Innovator in Monoclonal Antibodies

Introduction

Dana Duey is a prominent inventor based in San Diego, California. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of three patents to her name, Dana's work focuses on therapeutic and diagnostic methods for various diseases.

Latest Patents

Dana's latest patents include groundbreaking inventions such as anti-CD115 antibodies and anti-CD47 antibodies. The anti-CD115 monoclonal antibodies are designed for use in therapeutic and diagnostic methods aimed at treating cancer, autoimmune diseases, and other health conditions. Similarly, the anti-CD47 monoclonal antibodies provide innovative solutions for the treatment of cancer, ischemic-reperfusion injury, and other diseases.

Career Highlights

Throughout her career, Dana has worked with notable companies such as Ablexis, LLC and Absos, LLC. Her expertise in monoclonal antibody development has positioned her as a key player in the biotechnology sector. Dana's innovative approaches have led to advancements in therapeutic applications that benefit patients worldwide.

Collaborations

Dana has collaborated with esteemed colleagues, including John Lippincott and John A. Lippincott. These partnerships have fostered a collaborative environment that enhances the research and development of her inventions.

Conclusion

Dana Duey is a trailblazer in the field of monoclonal antibodies, with a focus on developing innovative solutions for serious health issues. Her contributions continue to impact the biotechnology industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…